United States - English - NLM (National Library of Medicine)

rebel distributors corp - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - adults risperdal® (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)] . adolescents risperdal® is indicated for the treatment of schizophrenia in adolescents aged 13–17 years [see clinical studies (14.1)] . monotherapy - adults and pediatrics risperdal® is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults and in children and adolescents aged 10–17 years [see clinical studies (14.2)] . combination therapy – adults the combination of risperdal® with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder [ see clinical studies (14.3)] . pediatrics risperdal® is indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5–16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [s

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 50 mg - injection, modified release - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; dibasic sodium phosphate dihydrate; sodium chloride; citric acid; carmellose sodium - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 37.5 mg - injection, modified release - excipient ingredients: citric acid; sodium chloride; carmellose sodium; polysorbate 20; dibasic sodium phosphate dihydrate; sodium hydroxide; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 25 mg - injection, modified release - excipient ingredients: sodium hydroxide; citric acid; sodium chloride; carmellose sodium; dibasic sodium phosphate dihydrate; polysorbate 20; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Israel - English - Ministry of Health

j-c health care ltd - risperidone - solution - risperidone 1 mg / 1 ml - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

j-c health care ltd - risperidone - film coated tablets - risperidone 1 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

j-c health care ltd - risperidone - film coated tablets - risperidone 2 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

j-c health care ltd - risperidone - film coated tablets - risperidone 3 mg - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; propylene glycol; maize starch; sodium lauryl sulfate; magnesium stearate; purified talc; iron oxide red; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).